![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Mirati Therapeutics’ KRAS Blocker Shrinks Tumors in Advanced Colon Cancer Patients
Mirati Therapeutics’ KRAS Blocker Shrinks Tumors in Advanced Colon Cancer Patients
![Mirati Therapeutics Logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Mirati-Therapeutics-Logo.png?t=1632180744&width=430)
September 21, 2021
Mirati Therapeutics’ adagrasib reduced tumors in 22 percent of colorectal cancer patients with a KRAS G12C gene mutation in a phase 1/2 trial.
Adagrasib combined with another anticancer therapy, cetuximab, reduced tumors by 43 percent in the early/mid-stage trial, the California-based company said.
If approved, adagrasib would compete with Amgen’s potential blockbuster cancer drug, Lumakras (sotorasib), which the FDA approved in May for the same indication.
Upcoming Events
-
21Oct